The Vasopressin V1b Receptor pipeline drugs market research report outlays comprehensive information on the Vasopressin V1b Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Vasopressin V1b Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Central Nervous System, Gastrointestinal, Respiratory, and Hematological Disorders which include the indications Major Depressive Disorder, Hepatorenal Syndrome, Unspecified Respiratory Disorders, and Anemia. It also reviews key players involved in Vasopressin V1b Receptor targeted therapeutics development with respective active and dormant or discontinued products.

The Vasopressin V1b Receptor pipeline targets constitutes close to six molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, and Phase II stages are 3, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.

Vasopressin V1b Receptor overview

Vasopressin V1b Receptor also known as the AVPR1B receptor that in humans is encoded by a gene AVPR1B. It is a G protein-coupled receptor (GPCR) that is part of the vasopressin receptor family. The natural ligand for the Vasopressin V1b Receptor is vasopressin, also known as arginine vasopressin (AVP). Vasopressin is a peptide hormone that plays a role in regulating water balance, blood pressure, and stress responses. This is primarily expressed in the anterior pituitary gland, where it mediates the effects of vasopressin on the release of adrenocorticotropic hormone (ACTH). Activation of this receptor can lead to the release of stress hormones by regulating the hypothalamic-pituitary-adrenal (HPA) axis, which is a key component of the body’s response to stress.

For a complete picture of Vasopressin V1b Receptor’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.